SCHEMBL3858656

SCHEMBL3858656

COC(=O)c1c(Br)cc(Br)cc1NC(=O)C(C)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.49
L3MBTL1 Q9Y468 3/20 0.48
LMNA P02545 2/20 0.48
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 3/20 0.44
GAA P10253 3/20 0.44
TP53 P04637 1/20 0.44
KCNQ2 O43526 1/20 0.43
POLB P06746 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
MAPT P10636 2/20 0.40
GFER P55789 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3856537 0.80 ALDH1A1 (0.46) PABPC1L3MBTL1LMNAMEN1KMT2A
SCHEMBL3861313 0.78 L3MBTL1 (0.48) PABPC1L3MBTL1LMNAMEN1KMT2A
SCHEMBL4081297 0.77 ALDH1A1 (0.60) L3MBTL1MEN1KMT2AALDH1A1GAA
SCHEMBL3860229 0.74 TSHR (0.66) L3MBTL1LMNAKMT2AALDH1A1GAA
SCHEMBL3858627 0.73 KMT2A (0.43) L3MBTL1LMNAMEN1KMT2AGAA
SCHEMBL3857037 0.72 MAPT (0.52) L3MBTL1LMNAMEN1KMT2AALDH1A1
SCHEMBL3862767 0.71 ALDH1A1 (0.54) L3MBTL1LMNAMEN1KMT2AALDH1A1
SCHEMBL4803910 0.68 ALDH1A1 (0.46) L3MBTL1MEN1KMT2AALDH1A1GAA
SCHEMBL22660771 0.67 ALDH1A1 (0.68) L3MBTL1LMNAMEN1KMT2AALDH1A1
SCHEMBL17365594 0.66 POLB (0.66) L3MBTL1LMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592457-B2 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-09-22 US disclosed
EP-1650190-A1 3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same Korea Research Institute of Chemical Technology (KR) 2006-04-26 EP disclosed
US-20060084676-A1 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084676-A1 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same HTR6, HTR3B, HTR2C PABPC1 4582/4885L3MBTL1 4135/4885LMNA 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.